Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Co-Diagnostics, Inc.

Get SEC filing alerts via email and in your feed for Co-Diagnostics, Inc.

CODX

Co-Diagnostics, Inc.

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc. develops and manufactures molecular diagnostic tests using proprietary PCR technology to detect infectious diseases and genetic traits. Its core products include PCR-based diagnostic kits for COVID-19, influenza, tuberculosis, HPV, and other pathogens, sold globally to clinical labs and health agencies. The company emphasizes affordable, rapid, and accurate testing solutions, with a focus on innovative platform development for point-of-care and at-home use.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Co-Diagnostics, Inc.

1
1
Co-Diagnostics, Inc. Co-Diagnostics Reports Increased Product Revenue but Faces Significant Losses in Q1 2026

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Co-Diagnostics, Inc. Co-Diagnostics Reports 84% Revenue Decline and Widened Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Co-Diagnostics, Inc. Co-Diagnostics Reports 77% Revenue Decline and $5.9M Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Co-Diagnostics, Inc. Co-Diagnostics Reports Significant Revenue Decline and Increased Net Loss in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Co-Diagnostics, Inc. Co-Diagnostics Reports 89% Revenue Decline and $7.5 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Co-Diagnostics, Inc. Co-Diagnostics Reports 43% Revenue Decline and Increased Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Co-Diagnostics, Inc. Co-Diagnostics Reports Significant Financial Decline, Net Loss Widens in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments